Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9.

Area of Science:

• Molecular Biology
• Immunotherapy
• Genetic Engineering

Background:

• The clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 (CRISPR/Cas9) system is a powerful RNA-guided DNA targeting technology.
• CRISPR/Cas9 has demonstrated significant potential for genetic manipulation across various biological applications.

Purpose of the Study:

• To review the current development of CRISPR/Cas9 technologies for therapeutic applications, focusing on chimeric antigen receptor (CAR) T cell-based adoptive immunotherapy.
• To compare different methods for efficient CRISPR delivery and gene editing in T cells.
• To explore the potential of CRISPR/Cas9 for generating universal CAR T cells resistant to exhaustion and inhibition.

Main Methods:

• Comparison of various CRISPR delivery and gene editing techniques in T cells.
• Exploration of CRISPR/Cas9 applications in generating enhanced CAR T cells.
• Discussion of safety concerns and potential solutions for CRISPR/Cas9 use in immunotherapy.

Main Results:

• CRISPR/Cas9 facilitates efficient gene editing in T cells for immunotherapy.
• The technology holds potential for creating universal CAR T cells and T cells resistant to exhaustion.
• CRISPR/Cas9 serves as an integration-free gene insertion method, acting as an efficient gene knock-in platform.

Conclusions:

• CRISPR/Cas9 technology is advancing CAR T cell immunotherapy with immense promise.
• The system offers efficient genetic manipulation for enhanced therapeutic outcomes.
• Addressing safety concerns is crucial for the future application of CRISPR/Cas9 in immunotherapy.